Regenxbio Inc (RGNX) down -17.90% since start of the year

Regenxbio Inc (NASDAQ: RGNX) is -17.90% lower on its value in year-to-date trading and has touched a low of $12.82 and a high of $25.54 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RGNX stock was last observed hovering at around $18.45 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $36.00 for the next 12 months. It is also 64.19% off the consensus price target high of $52.00 offered by 8 analysts, but current levels are 6.9% higher than the price target low of $20.00 for the same period.

Currently trading at $18.62, the stock is -4.67% and 4.86% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.05 million and changing 0.92% at the moment leaves the stock 0.79% off its SMA200. RGNX registered -20.97% loss for a year compared to 6-month gain of 1.09%. The firm has a 50-day simple moving average (SMA 50) of $6.12 and a 200-day simple moving average (SMA200) of -$2.60.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a -2.67% loss in the last 1 month and extending the period to 3 months gives it a 10.31%, and is -6.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.19% over the week and 4.97% over the month.

Regenxbio Inc (RGNX) has around 401 employees, a market worth around $819.09M and $99.37M in sales. Profit margin for the company is -262.18%. Distance from 52-week low is 45.24% and -27.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.27%).

Regenxbio Inc (RGNX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Regenxbio Inc (RGNX) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.00, where 3 rate it as a Hold and 2 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Regenxbio Inc is expected to release its quarterly report on 02/28/2024.The EPS is expected to grow by 18.33% this year.

Regenxbio Inc (RGNX) Top Institutional Holders

The shares outstanding are 43.30M, and float is at 39.82M with Short Float at 9.76%.

Regenxbio Inc (RGNX) Insider Activity

A total of 0 insider transactions have happened at Regenxbio Inc (RGNX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Mills Kenneth T.,the company’sPresident and CEO. SEC filings show that Mills Kenneth T. sold 45,000 shares of the company’s common stock on Dec 19 at a price of $19.68 per share for a total of $0.89 million. Following the sale, the insider now owns 0.36 million shares.

Regenxbio Inc disclosed in a document filed with the SEC on Jan 03 that PAKOLA STEVE (Chief Medical Officer) sold a total of 3,138 shares of the company’s common stock. The trade occurred on Jan 03 and was made at $22.17 per share for $69559.0. Following the transaction, the insider now directly holds 12175.0 shares of the RGNX stock.